(株)ミズホメディーの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証STD | 医薬品 | 4595/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2023/04/28 | 日証協 | 230,641株 | +1.75% | 16,216株 | -49.33% | 375,230株 | -1.15% | 184,878株 | -24.12% |
2023/04/21 | 日証協 | 226,673株 | -0.54% | 32,000株 | +113.33% | 379,614株 | +0.08% | 243,643株 | +834.75% |
2023/04/14 | 日証協 | 227,900株 | +5.36% | 15,000株 | +689.47% | 379,303株 | +0.53% | 26,065株 | -6.77% |
2023/04/07 | 日証協 | 216,300株 | +0.6% | 1,900株 | -86.9% | 377,294株 | +3.95% | 27,958株 | +108.53% |
2023/03/31 | 日証協 | 215,000株 | -1.6% | 14,500株 | +165.08% | 362,962株 | -2.24% | 13,407株 | -82.88% |
2023/03/24 | 日証協 | 218,500株 | -7.1% | 5,470株 | -96.15% | 371,287株 | -4.75% | 78,305株 | -56.28% |
2023/03/17 | 日証協 | 235,200株 | +102.24% | 142,200株 | +1445.65% | 389,786株 | +4.01% | 179,109株 | +16.67% |
2023/03/10 | 日証協 | 116,300株 | -18.53% | 9,200株 | 0% | 374,759株 | -1.55% | 153,520株 | +5.19% |
2023/03/03 | 日証協 | 142,760株 | -6.67% | 0株 | -100% | 380,655株 | -5.66% | 145,946株 | +95.61% |
2023/02/24 | 日証協 | 152,960株 | -8.93% | 800株 | -96.6% | 403,500株 | +9.77% | 74,612株 | +46.67% |
2023/02/17 | 日証協 | 167,960株 | -26.55% | 23,500株 | +312.28% | 367,584株 | -10.33% | 50,871株 | +112.37% |
2023/02/10 | 日証協 | 228,660株 | -2.93% | 5,700株 | 0% | 409,951株 | +1.35% | 23,954株 | -66.78% |
2023/02/03 | 日証協 | 235,560株 | -0.25% | 0株 | -100% | 404,497株 | +0.58% | 72,115株 | -52.38% |
2023/01/27 | 日証協 | 236,160株 | -9.75% | 10,300株 | -56.9% | 402,174株 | +0.46% | 151,432株 | +64.22% |
2023/01/20 | 日証協 | 261,660株 | -0.3% | 23,900株 | +16.02% | 400,346株 | -0.57% | 92,213株 | +220.08% |
2023/01/13 | 日証協 | 262,460株 | +0.54% | 20,600株 | +24.1% | 402,645株 | +1.62% | 28,809株 | -45.25% |
2023/01/06 | 日証協 | 261,060株 | +5.75% | 16,600株 | -73.75% | 396,238株 | +72.9% | 52,616株 | -78.37% |
2022/12/30 | 日証協 | 246,870株 | +18.86% | 63,250株 | +213.12% | 229,169株 | -21.05% | 243,283株 | +209.18% |
2022/12/23 | 日証協 | 207,700株 | -22.5% | 20,200株 | -78.71% | 290,253株 | -28.24% | 78,686株 | -18.48% |
※株式分割は考慮していませんのでご注意ください。
Page Top